Board of Directors
External Industry Leaders
Paul B. Cleveland, J.D.
Mr. Cleveland brings over 20 years of experience in strategic corporate transactions and investment banking to the Jennerex board. As executive vice president of corporate development and chief financial officer for Affymax, he manages all business development, strategic planning, financial and legal activities. Prior to Affymax, he served as managing director of the investment banks Integrated Finance, Ltd. and J.P. Morgan Chase and Co. (formerly Hambrecht & Quist), leading healthcare and technology mergers and acquisitions for the firms. Prior to his tenure in investment banking, he was a partner at Cooley Godward LLP. Mr. Cleveland serves as a member of the board of directors of Sangamo BioSciences, Inc. He holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.
Hoyoung Huh, M.D., Ph.D.
Dr. Huh has been involved in the formation and management of multiple biopharm companies. Most recently Dr. Huh was CEO of BiPar Sciences where he led the merger of BiPar with Sanofi-aventis (NYSE: SNY), and he now serves as Chairman of BiPar. He currently serves on the board of several other major biopharm companies, including Epizyme, Inc., Facet Biotech (NASDAQ: FACT), Interplast, and BayBio. Dr. Huh was previously a member of the Board and COO at Nektar Therapeutics (NASDAQ: NKTR), a drug development company focused on oncology, CNS/pain, diabetes and infectious diseases. At Nektar, Dr. Huh led partnerships with major pharmaceutical companies, including Bayer, Roche, Baxter, Novartis, and Pfizer. As an industry thought leader, Dr. Huh speaks frequently on innovation, entrepreneurship, and biotechnology strategies. Dr. Huh was formerly a Partner at McKinsey and Co., as a leader in the biotechnology sector. Dr. Huh holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a bachelor's degree in biochemistry from Dartmouth College.
Martin J. Murphy, Jr., PhD, DMedSc
Dr. Murphy is currently Chairman of the American Society for Clinical Oncology (ASCO) Foundation. He is also the Founding Chairman and CEO of the international, peer-reviewed journal, "The Oncologist", which is read by more than 21,000 physicians. He founded and was the CEO of the Hipple Cancer Research Center where he was principal investigator of $12M of cancer research grants. He is also founding convener of the CEO Roundtable on Cancer, first-chaired by Robert A. Ingram at the request of former President George H.W. Bush.
Barry Sherman, M.D.
Dr. Sherman has more than 30 years of experience in academic and pharmaceutical biomedical research and development, including his tenure as Genentech's first senior vice president and chief medical officer. Most recently, he was executive vice president and co-founder of BiPar Sciences where he led the development of the Company's lead product until its acquisition by Sanofi Aventis. He has served as president and chief executive officer of Anergen Inc., and was a founder of Pain Therapeutics, Inc. Prior to joining Genentech in 1985, Dr.Sherman was professor of medicine and endocrinology at the University of Iowa-College of Medicine, where he served as associate chairman of the department of internal medicine and director of the National Institutes of Health-sponsored Clinical Research Center. Dr. Sherman is a graduate of the University of Michigan in Ann Arbor, where he received both his A.B. and M.D.degrees with honors. He completed his clinical and research training at the Albert Einstein College of Medicine in New York, the NIH in Bethesda, Maryland, and the University of Michigan.
Additional Board Leadership
Brennan Mulcahy (Board Chairman)
Mr. Mulcahy is the former CEO of Energy Saving Income Fund, Toronto, ON, a publicly-traded company with sales of over 2 billion dollars last year. He has been involved in the deregulation of natural gas for 18 years.
Ken Newport, C.A., M.Acc.
Ken Newport of Ottawa, Canada was appointed to the Board in 2010. A chartered accountant, entrepreneur and life sciences business executive, Mr. Newport served as Senior Vice President and Executive Committee member at PRA International Inc. for three years until his retirement in 2005. In the mid-nineties he was co-founder and President of CroMedica Inc., a clinical trials contract research organization which was sold to PRA International in 2002. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is a member of the Institute of Corporate Directors and serves on the corporate Boards of The Opmedic Group, Jennerex Inc, and Medgenesis Therapeutics Inc. Mr. Newport earned Honours B.A. and Masters of Accounting degrees from the University of Waterloo.
Ron Vered, P.Eng
Mr. Vered is CEO of Arnon Corporation and past President of Ron Engineering and Construction (Eastern) Ltd., privately-owned real estate and construction companies based in Ottawa with international experience. Through the Vered Foundation, the Vered family has been active in and supportive of numerous causes including the United Jewish Appeal, the University of Ottawa Heart Institute, the University of Ottawa and the Ottawa Hospital. Mr. Vered is a Member of the Board of Trustees of S.C.O. Health Service and University of Ottawa Heart Institute.
Jennerex Management
John Bell, PhD, Chief Scientific Officer
David Kirn, M.D., CEO and Founder of Jennerex
Glen Sato, JD, MBA, Corporate Counsel
Glen Sato is a partner in the Life Sciences practice group at Cooley Godward in Palo Alto. Prior to rejoining Cooley in 2006, Mr. Sato most recently served as PDL's senior vice president and chief financial officer. He joined PDL from Exelixis, Inc., where he served as senior vice president, chief financial officer and general counsel from November 1999 to May 2003. Prior to his time at Exelixis, he served in various legal and strategic planning positions at PDL, including vice president, legal and general counsel. In addition, Mr. Sato worked for Steve Jobs at NeXT Computer, Inc. where he served as associate general counsel. He was an attorney in Cooley Godward's business department in Palo Alto for two years. Mr. Sato received his JD and MBA from UCLA, where he was an associate editor of the Law Review.
